ClinicalTrials.gov
ClinicalTrials.gov Menu

Studying a Tumor Marker for Testicular Cancer, Skin Cancer, Small Intestine Cancer, and Pancreatic Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00899132
Recruitment Status : Terminated (Study due for continuing review)
First Posted : May 12, 2009
Last Update Posted : September 29, 2015
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Case Comprehensive Cancer Center

May 9, 2009
May 12, 2009
September 29, 2015
February 2007
September 2012   (Final data collection date for primary outcome measure)
  • Identification of TAB3 transcript/protein as a molecular marker of cancer [ Time Frame: end of study ]
  • Characterization of TAB3 and its signaling networks that are involved in tumorigenesis [ Time Frame: end of study ]
  • Identification of TAB3 transcript/protein as a molecular marker of cancer
  • Characterization of TAB3 and its signaling networks that are involved in tumorigenesis
Complete list of historical versions of study NCT00899132 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Studying a Tumor Marker for Testicular Cancer, Skin Cancer, Small Intestine Cancer, and Pancreatic Cancer
The Role of TAB3 Protein in Tumorigenesis

RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.

PURPOSE: This research study is evaluating a tumor marker for testicular cancer, skin cancer, small intestine cancer, and pancreatic cancer.

OBJECTIVES:

  • To identify TAB3 transcript/protein as a molecular marker of cancer, specifically testicular, skin, small intestine, and pancreatic cancer.
  • To characterize TAB3 and its signaling networks that are involved in tumorigenesis.

OUTLINE: Tumor tissue samples from paraffin-embedded tissue blocks are analyzed for TAB3 transcript and protein expression using in situ hybridization and immunostaining with TAB3 cRNA probe and antibody. Antibodies against the proteins involved in the NFkB signaling pathway (e.g., p65, TAK1, MyD88, and Akt) are used in the immunostaining assays.

Observational
Observational Model: Case-Only
Time Perspective: Cross-Sectional
Not Provided
Retention:   Samples With DNA
Description:
Tumor tissue samples from paraffin-embedded tissue blocks.
Probability Sample
Primary care center
  • Non-melanomatous Skin Cancer
  • Pancreatic Cancer
  • Small Intestine Cancer
  • Testicular Germ Cell Tumor
  • Genetic: in situ hybridization
    Tumor tissue samples from paraffin-embedded tissue blocks are analyzed for TAB3 transcript and protein expression using in situ hybridization and immunostaining with TAB3 cRNA probe and antibody. Antibodies against the proteins involved in the NFkB signaling pathway (e.g., p65, TAK1, MyD88, and Akt) are used in the immunostaining assays.
  • Genetic: protein expression analysis
    Tumor tissue samples from paraffin-embedded tissue blocks are analyzed for TAB3 transcript and protein expression using in situ hybridization and immunostaining with TAB3 cRNA probe and antibody. Antibodies against the proteins involved in the NFkB signaling pathway (e.g., p65, TAK1, MyD88, and Akt) are used in the immunostaining assays.
  • Other: immunologic technique
    Tumor tissue samples from paraffin-embedded tissue blocks are analyzed for TAB3 transcript and protein expression using in situ hybridization and immunostaining with TAB3 cRNA probe and antibody. Antibodies against the proteins involved in the NFkB signaling pathway (e.g., p65, TAK1, MyD88, and Akt) are used in the immunostaining assays.
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
180
Not Provided
September 2012
September 2012   (Final data collection date for primary outcome measure)

DISEASE CHARACTERISTICS:

  • Paraffin tissue blocks from surgical pathology cancer cases, specifically testicular, skin, small intestine, and pancreatic cancer, available

PATIENT CHARACTERISTICS:

  • Not specified

PRIOR CONCURRENT THERAPY:

  • Not specified
Sexes Eligible for Study: All
Child, Adult, Older Adult
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00899132
CASE5Y06
P30CA043703 ( U.S. NIH Grant/Contract )
CASE5Y06 ( Other Identifier: Case Comprehensive Cancer Center )
CASE-5Y06-CC191 ( Other Identifier: Cancer Center IRB )
No
Not Provided
Not Provided
Case Comprehensive Cancer Center
Case Comprehensive Cancer Center
National Cancer Institute (NCI)
Study Chair: Ge Jin, PhD Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
Case Comprehensive Cancer Center
September 2015